Medigene AG consistent with the company's recent decision to focus its development efforts on solid tumors, the MDG1021 development program is to be discontinued. Recruitment for the Phase I clinical trial of the T cell receptor-modified T cell therapy MDG1021 directed against the antigen HA-1 in patients suffering from relapsed or persistent blood cancers after allogeneic (non-self) hematopoietic stem cell transplantation, which was initiated at the Leiden University Medical Centre (LUMC) in the Netherlands in mid-2020, will be put on hold with immediate effect. Discussions are ongoing with LUMC regarding the potential assumption of the sponsorship role by the LUMC with continuation of the study under LUMC's responsibility and return of the development and commercialization rights to the HA-1-specific TCR acquired from LUMC in November 2018.